USA2 SPOTLIGHT

A July 8, 2020 UsAgainstAlzheimer’s release quoted Chairman George Vradenburg regarding Biogen’s FDA filing for aducanumab, for the treatment of early Alzheimer’s disease. According to Vradenburg, “If approved, this drug would enable people with early stage Alzheimer’s to live with a higher quality of life for a longer period of time. Approval also would accelerate drug development and stimulate further investment of therapies and treatments throughout the pipeline and would represent a real turning point in the efforts to stop Alzheimer’s disease.”

MUST READS

According to a July 8, 2020 Biogen news release, Biogen completed its FDA filing for aducanumab, requesting priority review. “Alzheimer’s disease remains one of the greatest public health challenges of our time… The aducanumab BLA is the first filing for FDA approval of a treatment that addresses the clinical decline associated with this devastating condition, as well as the pathology of the disease. We are committed to driving progress for the Alzheimer’s disease community…” said Biogen’s Michel Vounatsos.

GLOBAL PERSPECTIVES

(ICYMI) A June 24, 2020 ISRAEL21c article spotlighted Harvard Medical School’s David Elmaleh, who is testing the efficacy of ALZT-OP1 in phase three clinical trials, for the treatment of early Alzheimer’s disease. The drug, which suppresses the immune system’s production of cytokines, which trigger inflammation, may also be effective in treating COVID-19. According to the article, “…The novel coronavirus pandemic hit the world and Elmaleh believed ALZT-OP1 could help patients with associated breathing distress caused by a cytokine storm. AZTherapies prepared a clinical trial protocol for the FDA and has approached several European countries and Israeli hospitals about trying its drug candidate on Covid-19 patients.”